OAsIs resistance score predicts a less favorable outcome in MCL. (A) The sign_clust5 score was computed based on the 742 genes characteristic of cluster #5 of patient MCL34, as represented in Figure 2E. The violin plot shows the sign_clust5 score for patients who achieved complete response (MCL36, MCL39), rapid relapse after the initial response (MCL34, MCL12), or progression (MCL10, MCL24). The analysis was performed at the whole sample level (upper panel) or at Seurat-computed cluster level (lower panel). Mann-Whitney test; ∗∗∗P < .001, ∗∗∗∗P < .0001. (B) Sixteen genes comprising a novel OAsIs resistance score (MCL_R16) based on the top genes of the sign_clust5 signature. (C) The MCL_R16 score was computed at Seurat-computed cluster level in MCL34 and MCL12 at the time of inclusion. Mann-Whitney test; ∗∗∗∗P < .0001. (D) Kaplan-Meier analyses of OS or PFS for the MCL_R16, cell-cycle, BCR, and NFκB signatures. Probabilities were calculated on 122 MCL patients treated with R-CHOP (GSE93291) or on 99 MCL patients included in the LYMA cohort (LYMA_RNA-seq) respectively. Blue curve: low score, red curve: high score. Log-rank test.